Clayton 2022 — Integrated Safety Profile Bremelanotide

Journal of Womens Health

Clayton AH, Kingsberg SA, Portman D, et al.

Summary

Mean SC 1.75 mg SBP/DBP rise +2-3 mmHg, peaking 0-4 h

Study Details

Study Design

Integrated safety analysis across 43 studies

Indication

Sexual dysfunction (female HSDD)

Intervention

0.75 / 1.25 / 1.75 mg

Species

Human

Sample Size

3,500 subjects

Risk of Bias Assessment

Industry-affiliated authorship